Merz Pharmaceuticals, the US subsidiary of German drugmaker Merz, develops and distributes prescription and over-the-counter pharmaceutical treatments for skin and nail care. The company's products include Mederma, which is used to reduce the appearance of scarring; Appearex, which treats weak and brittle nails; and Naftin, a topical antifungal. Merz also sells the Aqua Glycolic line of skin cleansers and moisturizers. The company distributes a handful of non-dermatology products developed by its parent company, and is conducting research into aesthetic dermatology products.

Depomed, Inc. was founded in 1995 and is based in Menlo Park, California. Depomed, Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary oral drug delivery technologies in the United States. It markets GLUMETZA for the treatment of type 2 diabetes in the United States, Canada, and Korea; and Proquin XR for treatment of uncomplicated urinary tract infection in the United States. Depomed company's under development products comprise DM-5689, a Phase III clinical trial product for the treatment of menopausal hot flashes; DM-1796, a Phase III clinical trial product for the treatment of postherpetic neuralgia, as well as is in Phase II clinical trail for diabetic peripheral neuropathy; DM-3458, a Phase I clinical trial product for the treatment of gastroesophageal reflux disease; and DM-1992, a Phase I clinical trial product that targets Parkinson's disease. It has collaboration and license agreements with PharmaNova, Inc.; Solvay Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Covidien Ltd.; Santarus, Inc.; Teva Pharmaceuticals USA, Inc.; Patheon, Inc.; Biovail Laboratories Incorporated; LG Life Sciences, Ltd.; Watson Pharmaceuticals, Inc.; and Rottapharm/Madaus S.r.l. The company sells its products to wholesalers and retail pharmacies.

The Westaim Corporation was founded in 1996. The Westaim Corporation, a holding company, develops, manufactures and commercializes medical products that fight infection and inflammation. Nucryst Pharmaceuticals Corp. Nucryst develops, manufactures and commercializes innovative medical products that fight infection and inflammation. Wound Care Products: Acticoat Burn Dressings and Acticoat 7 Dressings, targeting the burn and chronic wound markets, were developed and sold by Nucryst. Nucryst's license to Smith & Nephew grants Smith & Nephew the exclusive worldwide right to market, distribute and sell Acticoat products using Nucryst's SILCRYST coatings for use on non-minor dermal wounds or burns in humans, including improvements to those products, and any new products developed with Smith & Nephew using Nucryst's SILCRYST coatings or powders in the Field. There are six product families with SILCRYST coatings manufactured by Nucryst for Smith & Nephew at its Fort Saskatchewan plant: Acticoat Burn, Acticoat 7, Acticoat Absorbent, Acticoat Moisture Control, Acticoat Site, and Acticoat Post-Op. In 2008, Nucryst announced that Health Canada granted marketing approval for a new SILCRYST product, Acticoat Flex Barrier Dressing. Agreements with Smith & Nephew: In 2007, Nucryst signed amended agreements with Smith & Nephew for the manufacture and sale of Acticoat products.

Prestige Brands Holdings was founded in 1996 and is headquartered in Irvington, New York. Prestige Brands Holdings, Inc. (Prestige) sells over-the-counter healthcare, household cleaning and personal care products in a global marketplace. The Company’s products are sold through multiple channels, including mass merchandisers and drug, grocery, dollar and club stores, which allow it to launch products across all distribution channels and reduce its exposure to any single distribution channel. The Company conducts its operations through three principal business segments: over-the-counter healthcare, household cleaning and personal care. During the fiscal year ended March 31, 2009 (fiscal 2009), Prestige’s principal brands accounted for approximately 94.5% of its net revenues.

Nabi Biopharmaceuticals company was founded in 1967 and is headquartered in Rockville, Maryland. Nabi Biopharmaceuticals, a biopharmaceutical company, develops products that address unmet medical needs in the areas of nicotine addiction and infectious disease in the United States. The company is developing NicVAX, a proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. It has a manufacturing services agreement with Biotest Pharmaceuticals Corporation, which enables it to obtain clinical lots of its retained products, as well as component products from Biotest. Nabi Biopharmaceuticals also has license and royalty agreements with National Institute of Allergy and Infectious Diseases; National Institute for Drug Abuse; Department of Defense; National Institutes of Health; and University of Maryland.

GlaxoSmithKline plc company was founded in 1935 and is based in Brentford, the United Kingdom. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health related consumer products. The company offers prescription medicines to treat a range of conditions, such as infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets approximately 25 vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company offers OTC medicines, such as alli, a weight loss medicine; Panadol, a paracetamol/acetaminophen analgesic; smoking control products under the NicoDerm, NiQuitin CQ, Nicabate, and Nicorette names; and other brands, including Breathe Right nasal strips and Tums. Its oral healthcare products primarily comprise Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes, including Pronamel to protect from acid erosion; Biotene, a treatment for dry mouth; and Polident, PoliGrip, and Corega, which are denture care cleansers and adhesives. Further, the company provides nutritional healthcare products, such as Lucozade, a range of energy and sports drinks; Horlicks, a range of milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. GlaxoSmithKline operates in Europe, North America, Central and South America, the Caribbean, Asia, Australia, the Middle East, Africa, and the Southeast Asia.

GlaxoSmithKline Pharmaceuticals (GSK India) is the top of the pill heap. India's leading pharmaceutical manufacturer, the company makes pharmaceuticals and consumer health care products through its two manufacturing facilities in Nashik and Thane; it also has a clinical development center in Bangalore. Its products include those targeting problems with infections, gynecology, dermatology, diabetes, and the cardiovascular system. Top sellers are Augmentin, Zinetac, Calpol, Phexin, and Betnesol. GSK India also makes vaccines to treat or prevent hepatitis A and B, the flu, chickenpox, and tetanus. Its distribution network stretches throughout the country. UK-based drugmaker GlaxoSmithKline owns GSK India.

BioCryst Pharmaceuticals, Inc. was founded in 1986 and is based in Birmingham, Alabama. BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The company has progressed two compounds into late-stage pivotal clinical trials comprising Peramivir, an anti-viral for influenza; and Forodesine, a purine nucleoside phosphorylase (PNP) inhibitor forcutaneous T-cell lymphoma (CTCL). Peramivir is being developed under a contract from the Biomedical Advanced Research and Development Authority (BARDA) within the United States Department of Health and Human Services (HHS).Forodesine has been granted Orphan Drug status by the FDA for three indications, including T-cell non-Hodgkin's lymphoma, including CTCL; CLL and related leukemias, such as T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for the treatment of B-ALL. BioCryst Pharmaceuticals is also testing BCX4208, a second generation PNP inhibitor, which is in a Phase II study for the treatment of gout. The company utilizes crystallography and structure-based drug design to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. It has strategic alliances with the U.S. Department of Health and Human Services; Shionogi & Co., Ltd.; Green Cross Corporation; and Mundipharma International Holdings Limited.

AlphaRx, Inc., a pharmaceutical company, engages in the research and development of therapeutic products in Canada. The company is developing novel formulations of existing drugs that are insoluble or poorly soluble in water, utilizing its proprietary Bioadhesive Colloidal Dispersion drug delivery systems. Its principal products include Indaflex, a topical cream for the treatment of osteoarthritis of the knee; and Zysolin, an inhaled Tobramycin nanoparticles intended for the adjunctive treatment of Pseudomonas aeruginosa pneumonia in intubated and mechanically-ventilated patients. Indaflex completed a Phase II Proof of Concept clinical trial and Zysolin is in pre clinical stage. The company was formerly known as Logic Tech International, Inc. and changed its name to AlphaRx, Inc. in January 2000. AlphaRx, Inc. was founded in 1997 and is based in Markham, Canada.

Protide Pharmaceuticals is pro-cell. The firm focuses on developing new technologies for cellular and transfusion therapies, including gene therapies, to treat cancer and genetic disorders and to improve cell transplantation and engineering. To fund its work, Protide sells nearly 20 products under the Celox Laboratories brand to its academic, drug, and diagnostic research clients around the world. These products include serum-free growth mediums and supplements, as well as solutions used to cryopreserve cells and tissues. ICN Pharmaceuticals has a non-exclusive global marketing agreement for certain products. Protide also has a private-label manufacturing deal with a division of Sigma-Aldrich.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.